
Fact Sheet for Health Care Providers: Emergency Use Authorization (EUA) of CASIRIVIMAB and IMDEVIMAB
Item
Click for External Resource*
*The link above may share a zip file (.zip) hosted on repository.netecweb.org. Zip files will download automatically.
*All other links are external and will open in a new window. If you click an external link, you are leaving the NETEC site, and we do not maintain, review, or endorse these materials. See our terms of use.
Files for Download

Item Type
GuideTerms of Use
By accessing these materials you are agreeing to our terms of use, which may be found here: Terms of Use.
Document Viewer
Title
Fact Sheet for Health Care Providers: Emergency Use Authorization (EUA) of CASIRIVIMAB and IMDEVIMAB
Subject
Description
Casirivimab and imdevimab to be administered together for the treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization.
Date
2020-11-21
Citation
Download Heathcare Providers Fact Sheet directly: https://www.fda.gov/media/145611/download
Download Patients, Parents, and Caregivers Fact Sheet directly: https://www.fda.gov/media/145612/download
Download the Frequently Asked Questions on the Emergency Use Authorization of Casirivimab + Imdevimab
Was this resource helpful?